SABCS 2021 | ALTTO: impact of EPO administration concomitantly with adjuvant anti-HER2 treatment on outcomes

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, discusses the findings of a post-hoc analysis aiming to assess if erythropoietin (EPO) intake during the adjuvant anti-HER2 treatment impacted the outcomes of HER2-positive early breast cancer in patients enrolled in the ALTTO trial (NCT00490139). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.